Publikationen in Zusammenarbeit mit Forschern von United States Food and Drug Administration (10)

2024

  1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

2022

  1. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384

2021

  1. Minimal residual disease in Myeloma: Application for clinical care and new drug registration

    Clinical Cancer Research, Vol. 27, Núm. 19, pp. 5195-5212

2018

  1. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598

  2. Rating scales for cognition in Huntington's disease: Critique and recommendations

    Movement Disorders, Vol. 33, Núm. 2, pp. 187-195

2010

  1. Human peripheral blood B-Cell compartments: A crossroad in B-cell traffic

    Cytometry Part B - Clinical Cytometry, Vol. 78, Núm. SUPPL. 1

2007

  1. ZAP70 editorial: A follow-up to the special issue

    Cytometry Part B - Clinical Cytometry

2006

  1. ZAP-70 in CLL: Towards standardization of a biomarker for patient management: History of clinical cytometry special issue

    Cytometry Part B - Clinical Cytometry

2004

  1. Homocysteine as a predictive factor for hip fracture in older persons [1] (multiple letters)

    New England Journal of Medicine

1998

  1. Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates

    Journal of Clinical Microbiology, Vol. 36, Núm. 4, pp. 958-964